Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis’s Rhapsido clears two Phase III hurdles, sending its stock soaring.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 13.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
Source diversity sample: FirstWord Pharma · The Pharma Letter · Multiple Sclerosis News Today · Dealroom · TipRanks · Stocktwits · Investopedia · pharmaphorum.com.
How this dossier is built: methodology · AI policy · corrections.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
Rhapsido, a BTK inhibitor, achieved the prespecified endpoints in both Phase III trials for relapsing MS, according to the Pharma Letter and BioPharma Dive. Coverage diverges on the magnitude of benefit. Multiple Sclerosis News Today highlighted the drug’s superiority but offered no numerical comparison, while Endpoints News emphasized a safety edge without detailing adverse‑event rates.
Reuters mentioned “beats older drug” but stopped short of quantifying the gap. TGTX’s Stocktwits post dismissed competition yet provided no data on head‑to‑head trials, leaving the comparative efficacy picture incomplete. The positive readout has revived expectations for Novartis’s broader neurology portfolio.
What remains unclear are the long‑term safety profile and the timeline for regulatory submission. Neither Reuters nor the WSJ disclosed when Novartis plans to file for approval, and data on durability of response beyond the trial period are absent. Future updates on post‑marketing surveillance and any pending head‑to‑head studies will determine how the drug reshapes treatment algorithms.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (56% supported) Updated 1h ago.
Coverage (14)
- Novartis' Rhapsido delivers dual Phase III wins in relapsing MS FirstWord Pharma · 3d ago
- Novartis BTK inhibitor clears Phase III hurdle in relapsing MS The Pharma Letter · 3d ago
- Experimental oral MS drug outperforms approved therapy in 2 trials Multiple Sclerosis News Today · 3d ago
- Novartis' Rhapsido (remibrutinib) hits both Phase 3 goals in relapsing multiple sclerosis Dealroom · 3d ago
- Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials TipRanks · 3d ago
- TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis Stocktwits · 3d ago
- Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping Investopedia · 3d ago
- Novartis sets sights on new oral MS drug after phase 3 wins pharmaphorum.com · 3d ago
- Novartis says MS pill succeeds in two large studies BioPharma Dive · 3d ago
- Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up Investor's Business Daily · 3d ago
- Novartis' oral multiple sclerosis drug meets main goal in late stage studies finance.yahoo.com · 3d ago
- Novartis’ Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest Endpoints News · 3d ago
- Novartis MS pill beats older drug in trials, boosts pipeline hopes Reuters · 3d ago
- Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials WSJ · 3d ago
The obvious questions
What is Rhapsido?
Rhapsido (remibrutinib) is a BTK inhibitor developed by Novartis for the treatment of relapsing multiple sclerosis.
Which trials did Rhapsido succeed in?
The drug met its primary endpoints in two Phase III trials evaluating relapse rate and confirmed disability progression in relapsing MS patients.
How did the market respond to the trial results?
Novartis shares jumped on the news, with finance.yahoo.com and TipRanks reporting a notable price increase on September 1, 2026.
Topics
Related trends
Scientists uncover shared biology behind profound fatigue in five major illnesses
A new study finds a shared biological signature linking five fatigue‑related illnesses, opening doors for unified therapies.
Novartis inks $3.2B subcutaneous delivery deal with Alteogen
9 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers have halted autoimmune CAR-T trials after three patient deaths.
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers have paused CAR-T trials after patient deaths, raising safety concerns in the biopharma industry.
Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months
Novartis’s IL‑6 blocker Pacibekitug slashes inflammation markers for half a year, sparking debate over its heart‑benefit potential.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.